Lyra Therapeutics Inc
Company Profile
Business description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company’s operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Contact
480 Arsenal Way
WatertownMA02472
USAT: +1 617 393-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.60 | 29.50 | 0.33% |
| CAC 40 | 8,199.92 | 50.42 | 0.62% |
| DAX 40 | 24,578.41 | 88.00 | 0.36% |
| Dow JONES (US) | 47,999.44 | 63.85 | -0.13% |
| FTSE 100 | 9,974.06 | 42.68 | 0.43% |
| HKSE | 26,338.47 | 707.93 | 2.76% |
| NASDAQ | 23,459.68 | 217.69 | 0.94% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,873.12 | 27.62 | 0.40% |
| S&P/ASX 200 | 8,727.80 | 27.10 | 0.31% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |